FDA Creates Web Page with Drug Safety Information for Patients, Health Care Professionals
Tuesday, November 25th, 2008A wide variety of safety information about prescription drugs can now be accessed though a single FDA Web page , Postmarket Drug Safety Information for Patients and Providers.
Links are provided in these areas:
* Drug labeling, including patient labeling, professional labeling, and patient package inserts
* Drugs that have a Risk Evaluation and Mitigation Strategy (REMS) to ensure that their benefits outweigh their risks
* A searchable database of postmarket studies that are required from, or agreed to by, drug companies to provide the FDA with additional information about a drug’s safety, efficacy, or optimal use
* Clinicaltrials.gov, a searchable database of clinical trials, including information about each trial’s purpose, who may participate, locations, and useful phone numbers
* Drug-specific safety information, including safety sheets with the latest information about the drug as well as related FDA press announcements, fact sheets, and drug safety podcasts
* Quarterly reports that list certain drugs that are being evaluated for potential safety issues, based on a review of information in the FDA’s Adverse Event Reporting System (AERS)
* Warning Letters, Import Alerts, Recalls, Market Withdrawals, and Safety Alerts
* Regulations and guidance documents
* Consumer information about using medications safely and disposing of unused medicines
* Instructions how to report problems to the FDA through its MedWatch program
* Consumer articles on drug safety
* The FDA’s response to the Institute of Medicine’s 2006 report on the future of drug safety.
Please do not hesitate to contact Mulford Reference Assistance if there are any questions or if we may be of further assistance.
The American Association of Clinical Endocrinologists recently launched